Literature DB >> 12150196

Safety issues related to the administration of ribavirin.

Leonard R Krilov1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12150196     DOI： 10.1097/00006454-200205000-00037

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  20 in total

1.  Inhibitory Effect of PIK-24 on Respiratory Syncytial Virus Entry by Blocking Phosphatidylinositol-3 Kinase Signaling.

Authors:  Li-Feng Chen; Wei-Bin Xu; Yue-Yue Li; Neng-Hua Chen; Ding Luo; Qiao-Yun Song; Wei Tang; Zhi-Gang Huang; Yao-Lan Li; Zhong Liu; Man-Mei Li
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.

Authors:  Paul Zarogoulidis; Ellada Eleftheriadou; Iordanis Sapardanis; Vasiliki Zarogoulidou; Helliel Lithoxopoulou; Theodoros Kontakiotis; Nikolaos Karamanos; George Zachariadis; Maria Mabroudi; Athanasios Zisimopoulos; Kostantinos Zarogoulidis
Journal:  Invest New Drugs       Date:  2011-07-08       Impact factor: 3.850

3.  Respiratory syncytial virus: diagnosis, treatment and prevention.

Authors:  Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

4.  RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction.

Authors:  Rachael M Liesman; Ursula J Buchholz; Cindy L Luongo; Lijuan Yang; Alan D Proia; John P DeVincenzo; Peter L Collins; Raymond J Pickles
Journal:  J Clin Invest       Date:  2014-04-08       Impact factor: 14.808

5.  MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.

Authors:  Brian E Gilbert; Matthew T McLeay
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

6.  Effects of pegylated interferon alpha-2a on hepatitis-C-virus-associated glomerulonephritis.

Authors:  Tokio Sugiura; Takuji Yamada; Yuri Kimpara; Naoya Fujita; Kenji Goto; Norihisa Koyama
Journal:  Pediatr Nephrol       Date:  2008-08-12       Impact factor: 3.714

7.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection.

Authors:  Malgorzata Pawlowska; Malgorzata Pilarczyk; Anna Foksinska; Ewa Smukalska; Waldemar Halota
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

9.  Managing pediatric hepatitis C: current and emerging treatment options.

Authors:  Wikrom Karnsakul; Mary Kay Alford; Kathleen B Schwarz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

Review 10.  Emerging drugs for respiratory syncytial virus infection.

Authors:  Wieslawa Olszewska; Peter Openshaw
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.